Graig Suvannavejh, Biotech and Biopharma Analyst at Mizuho Amercas, says Oral GLP-1 obesity drugs and looming patent cliffs will drive big pharma into biotech M&A, especially in oncology, immunology and neurology.
Suvannavejh: The obesity space has become a major focus for investors
January 12, 2026
